A comprehensive review of viral characteristics, transmission, pathophysiology, immune response, and management of SARS-CoV-2 and COVID-19 as a basis for …
COVID-19 emerged from China in December 2019 and during 2020 spread to every
continent including Antarctica. The coronavirus, SARS-CoV-2, has been identified as the …
continent including Antarctica. The coronavirus, SARS-CoV-2, has been identified as the …
SARS-CoV-2 neutralizing antibodies for COVID-19 prevention and treatment
D Li, GD Sempowski, KO Saunders… - Annual review of …, 2022 - annualreviews.org
Prophylactic and therapeutic drugs are urgently needed to combat coronavirus disease
2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV …
2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV …
An infectious SARS-CoV-2 B. 1.1. 529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies
The emergence of the highly transmissible B. 1.1. 529 Omicron variant of severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) is concerning for antibody …
respiratory syndrome coronavirus 2 (SARS-CoV-2) is concerning for antibody …
Bamlanivimab plus etesevimab in mild or moderate Covid-19
M Dougan, A Nirula, M Azizad… - … England Journal of …, 2021 - Mass Medical Soc
Background Patients with underlying medical conditions are at increased risk for severe
coronavirus disease 2019 (Covid-19). Whereas vaccine-derived immunity develops over …
coronavirus disease 2019 (Covid-19). Whereas vaccine-derived immunity develops over …
[HTML][HTML] SARS-CoV-2 variants B. 1.351 and P. 1 escape from neutralizing antibodies
The global spread of SARS-CoV-2/COVID-19 is devastating health systems and economies
worldwide. Recombinant or vaccine-induced neutralizing antibodies are used to combat the …
worldwide. Recombinant or vaccine-induced neutralizing antibodies are used to combat the …
SARS-CoV-2 immune evasion by the B. 1.427/B. 1.429 variant of concern
A novel variant of concern (VOC) named CAL. 20C (B. 1.427/B. 1.429), which was originally
detected in California, carries spike glycoprotein mutations S13I in the signal peptide …
detected in California, carries spike glycoprotein mutations S13I in the signal peptide …
[HTML][HTML] Antibody resistance of SARS-CoV-2 variants B. 1.351 and B. 1.1. 7
The COVID-19 pandemic has had widespread effects across the globe, and its causative
agent, SARS-CoV-2, continues to spread. Effective interventions need to be developed to …
agent, SARS-CoV-2, continues to spread. Effective interventions need to be developed to …
[HTML][HTML] Increased resistance of SARS-CoV-2 variant P. 1 to antibody neutralization
The emergence of SARS-CoV-2 variants has raised concerns about altered sensitivity to
antibody-mediated immunity. The relative resistance of SARS-CoV-2 variants B. 1.1. 7 and …
antibody-mediated immunity. The relative resistance of SARS-CoV-2 variants B. 1.1. 7 and …
Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial
Importance Coronavirus disease 2019 (COVID-19) continues to spread rapidly worldwide.
Neutralizing antibodies are a potential treatment for COVID-19. Objective To determine the …
Neutralizing antibodies are a potential treatment for COVID-19. Objective To determine the …
LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants
K Westendorf, S Žentelis, L Wang, D Foster… - Cell reports, 2022 - cell.com
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-neutralizing monoclonal
antibodies (mAbs) can reduce the risk of hospitalization from coronavirus disease 2019 …
antibodies (mAbs) can reduce the risk of hospitalization from coronavirus disease 2019 …